

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

10.19.21

-

-

The
Company
expects
to
hold
a
Research
&
Development
event
to

breakthrough

findings

in

Q4

2021

that

will

be

open

to

the

public,

shareholders,

analysts

and

the

media-

-

TORONTO,

CANADA

-

October 19,

2021

-

(NEO:CYBN)

(NYSE

American:CYBN)

("**Cybin**"

or

the

"Company"),

a

biotechnology

company

focused

on

progressing

psychedelic

therapeutics,

today

announced

the

completion

of

its

74thpre-

clinical

study

as

to
progress
its
proprietary
psychedelic
molecules
into
Investigational
New
Drug
("IND")-
enabling
studies.

Cybin's
Research
and
Development
team
has
completed
74
in-
vitro
and

evaluations
of
Cybin's
expanding
portfolio
of
psychedelic
compounds
being
designed
for
potential
therapeutic
applications
for
several
mental
health
conditions.
To
date,
more
than
50
novel

been
evaluated
through
collaborations
with
experienced
contract
research
organizations
for
pharmacokinetic/pharmacodynamic
profile,
metabolic
stability,
receptor
binding,
and
safety
in
order
to
identify
preferred
candidates
for

The
Company
aims
to
create
a
world
class
portfolio
of
psychedelic
molecules
that
can
become
commercially
viable
drug
candidates
for
both
internal
development
and

development
partnerships.

Research
and
development
highlights:

-

Cybin

Our Work

Investors

About Us







“Cybin
continues
to
demonstrate
superior
properties
of

and
CYB004
programs
as
we
progress
toward
first-
in-
human
studies,
expected
in
early
2022.
These
experiments
greatly
expand
our
understanding
of
the
potential
therapeutic

the
studied
compounds
and
further
demonstrate
Cybin's
strong
research
and
development
capabilities,"
said
Doug
Drysdale,
Cybin's
CEO.

About

Cybin

Cybin
is
a
leading
biotechnology

on
progressing
psychedelic
therapeutics
by
utilizing
proprietary
drug
discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens
for
psychiatric
disorders.

**and
Forward-
Looking
Statements**

Certain
statements
in
this
press
release
constitute
forward-
looking
information.

All
statements
other
than
statements
of
historical
fact
contained
in

release,
including,
without
limitation,
statements
regarding
Cybin's
future,
strategy,
plans,
objectives,
goals
and
targets,
and
any
statements
preceded
by,
followed
by
or
that
include
the

“expect”,
“aim”,
“intend”,
“plan”,
“continue”,
“will”,
“may”,
“would”,
“anticipate”,
“estimate”,
“forecast”,
“predict”,
“project”,
“seek”,
“should”
or
similar
expressions
or
the
negative
thereof,
are
forward-
looking

looking
statements
in
this
news
release
include
statements
regarding
the
Company's
proprietary
drug
discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens

treat
psychiatric
disorders.

These
forward-
looking
statements
are
based
on
reasonable
assumptions
and
estimates
of
management
of
the
Company
at
the
time
such
statements

Actual
future
results
may
differ
materially
as
forward-
looking
statements
involve
known
and
unknown
risks,
uncertainties,
and
other
factors
which
may
cause
the
actual
results,

achievements
of
the
Company
to
materially
differ
from
any
future
results,
performance,
or
achievements
expressed
or
implied
by
such
forward-
looking
statements.
Such
factors,
among

include:
implications
of
the
COVID-
19
pandemic
on
the
Company's
operations;
fluctuations
in
general
macroeconomic
conditions;
fluctuations
in
securities
markets;
expectations
regarding
the
size
of

market;
the
ability
of
the
Company
to
successfully
achieve
its
business
objectives;
plans
for
growth;
political,
social
and
environmental
uncertainties;
employee
relations;
the
presence
of

regulations
that
may
impose
restrictions
in
the
markets
where
the
Company
operates;
and
the
risk
factors
set
out
in
the
Company's
management's
discussion
and
analysis

period
ended
June
30,
2021
and
the
Company's
listing
statement
dated
November
9,
2020,
which
are
available
under
the
Company's
profile
on
www.sedar.com
and
with

Securities
and
Exchange
Commission
on
EDGAR
at
www.sec.gov.

Although
the
forward-
looking
statements
contained
in
this
news
release
are
based
upon
what
management
of
the

or
believed
at
the
time,
to
be
reasonable
assumptions,
the
Company
cannot
assure
shareholders
that
actual
results
will
be
consistent
with
such
forward-
looking
statements,

may
be
other
factors
that
cause
results
not
to
be
as
anticipated,
estimated
or
intended.

Readers
should
not
place
undue
reliance
on
the
forward-
looking

information
contained
in
this
news
release.

The
Company
assumes
no
obligation
to
update
the
forward-
looking
statements
of
beliefs,
opinions,
projections,
or
other
factors,
should

except
as
required
by
law.

Cybin
makes
no
medical,
treatment
or
health
benefit
claims
about
Cybin's
proposed
products.

The
U.S.
Food
and
Drug
Administration,

or
other
similar
regulatory
authorities
have
not
evaluated
claims
regarding
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceutical
products.
The
efficacy
of

has
not
been
confirmed
by
approved
research.

There
is
no
assurance
that
the
use
of
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or

diagnose,
treat,
cure
or
prevent
any
disease
or
condition.

Vigorous
scientific
research
and
clinical
trials
are
needed.

Cybin
has
not
conducted
clinical
trials
for
the

its
proposed
products.
Any
references
to
quality,
consistency,
efficacy
and
safety
of
potential
products
do
not
imply
that
Cybin
verified
such
in
clinical
trials
or

will
complete
such
trials.
If
Cybin
cannot
obtain
the
approvals
or
research
necessary
to
commercialize
its
business,
it
may
have
a
material
adverse
effect
on

and
operations.

*Neither
the
Neo
Exchange
Inc.
nor
the
NYSE
American
LLC
stock
exchange
have
approved
or
disapproved
the
contents
of
this
news*

*are
not
responsible
for
the
adequacy
and
accuracy
of
the
contents
herein.*

Investor

Contacts:

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

Cybin@kcsa.com

Lisa

M.

Site

Communications,
Inc.

lwilson@insitecony.com

Media

Contact:

John

Kanakis

Cybin

Inc.

John@cybin.com

PREVIOUS POST

NEXT POST

Cybin

Cybin

5600-100 King St W, Toronto ON
M5X 1C9
Investor Contact: ir@cybin.com
General Contact:
info@cybin.com

Our Work

Investors

About Us

OUR WORK

INVESTORS

ABOUT US

Development Pipeline

Press Releases

Mission

The Science

Financials

Team

Cybin x Kernel

Corporate Governance

News

Downloads

Join Us

Contact



Copyright Cybin Corp. © 2021 . All rights reserved.

[Privacy Policy](#)